Compare Stocks

Date Range: 

 AlectorAlloVirREGENXBIOImmunovantReplimune Group
SymbolNASDAQ:ALECNASDAQ:ALVRNASDAQ:RGNXNASDAQ:IMVTNASDAQ:REPL
Price Information
Current Price$16.72$22.83$35.78$15.47$37.11
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.51.61.61.5
Analysis Score3.53.53.43.53.5
Community Score2.43.32.73.72.4
Dividend Score0.00.00.00.00.0
Ownership Score0.80.01.70.81.7
Earnings & Valuation Score0.00.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$34.40$49.25$62.50$44.93$56.00
% Upside from Price Target105.74% upside115.72% upside74.68% upside190.45% upside50.90% upside
Trade Information
Market Cap$1.33 billion$1.49 billion$1.52 billion$1.52 billion$1.73 billion
Beta1.08N/A1.28N/A2.63
Average Volume621,345340,663433,9141,310,016381,295
Sales & Book Value
Annual Revenue$21.22 millionN/A$35.23 millionN/AN/A
Price / Sales62.85N/A43.17N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.83 per shareN/A$12.23 per share$1.45 per share$5.01 per share
Price / Book5.91N/A2.93N/AN/A
Profitability
Net Income$-105,390,000.00N/A$-94,730,000.00$-66,390,000.00$-52,630,000.00
EPS($1.71)N/A($3.26)($1.54)($1.54)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-757.78%N/A-63.13%N/AN/A
Return on Equity (ROE)-53.86%N/A-21.73%-34.80%-30.23%
Return on Assets (ROA)-31.44%N/A-18.74%-32.38%-24.66%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.13%
Current Ratio6.61%28.40%6.08%35.15%19.47%
Quick Ratio6.61%28.40%6.08%35.15%19.47%
Ownership Information
Institutional Ownership Percentage61.50%32.07%75.23%40.21%55.79%
Insider Ownership Percentage13.90%1.00%14.10%0.24%50.90%
Miscellaneous
Employees1715330642122
Shares Outstanding79.77 million65.11 million42.51 million97.97 million46.49 million
Next Earnings Date8/10/2021 (Estimated)9/1/2021 (Estimated)8/5/2021 (Estimated)7/5/2021 (Estimated)6/2/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Analysts Expect Replimune Group, Inc. (NASDAQ:REPL) to Post -$0.41 EPS Analysts Expect Replimune Group, Inc. (NASDAQ:REPL) to Post -$0.41 EPS
americanbankingnews.com - May 11 at 9:24 PM
Replimune Group (NASDAQ:REPL) Trading 4.1% Higher Replimune Group (NASDAQ:REPL) Trading 4.1% Higher
americanbankingnews.com - May 11 at 11:42 AM
Replimune Appoints Tanya Lewis as Chief Development Operations OfficerReplimune Appoints Tanya Lewis as Chief Development Operations Officer
finance.yahoo.com - May 10 at 8:43 AM
Replimune Group (NASDAQ:REPL) vs. AVROBIO (NASDAQ:AVRO) Head-To-Head AnalysisReplimune Group (NASDAQ:REPL) vs. AVROBIO (NASDAQ:AVRO) Head-To-Head Analysis
americanbankingnews.com - May 10 at 5:12 AM
Replimune Group (NASDAQ:REPL) & Ocugen (NASDAQ:OCGN) Financial ComparisonReplimune Group (NASDAQ:REPL) & Ocugen (NASDAQ:OCGN) Financial Comparison
americanbankingnews.com - May 6 at 7:22 AM
Replimune Group (NASDAQ:REPL) Shares Gap Up to $32.53Replimune Group (NASDAQ:REPL) Shares Gap Up to $32.53
americanbankingnews.com - May 5 at 12:37 PM
BRIEF-Replimune Provides A Regulatory Update For Its Registration- Directed Clinical Trials Evaluating RP1 In Combination With LibtayoBRIEF-Replimune Provides A Regulatory Update For Its Registration- Directed Clinical Trials Evaluating RP1 In Combination With Libtayo
msn.com - May 5 at 12:17 PM
Replimune Provides A Regulatory Update For Its Registration- Directed Clinical Trials Evaluating RP1 In Combination With LibtayoReplimune Provides A Regulatory Update For Its Registration- Directed Clinical Trials Evaluating RP1 In Combination With Libtayo
cmlviz.com - May 5 at 12:17 PM
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed MelanomaReplimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
finance.yahoo.com - May 5 at 7:17 AM
Replimune Group (NASDAQ:REPL) Shares Down 7.5% Replimune Group (NASDAQ:REPL) Shares Down 7.5%
americanbankingnews.com - May 4 at 1:14 PM
Replimune Group, Inc. (NASDAQ:REPL)’s 16.12% Gain This Week Just Tells Us Something NewReplimune Group, Inc. (NASDAQ:REPL)’s 16.12% Gain This Week Just Tells Us Something New
marketingsentinel.com - May 1 at 6:25 PM
Replimune Group Inc (REPL)Replimune Group Inc (REPL)
investing.com - April 29 at 2:22 PM
Replimune to Host Virtual Investor Event on June 3, 2021Replimune to Host Virtual Investor Event on June 3, 2021
finance.yahoo.com - April 28 at 1:06 PM
Chutes & Ladders—Replimune, prepping for market, taps Genentech oncology vet as CMOChutes & Ladders—Replimune, prepping for market, taps Genentech oncology vet as CMO
fiercebiotech.com - April 25 at 12:23 PM
Analysts See Plenty of Upside for ReplimuneAnalysts See Plenty of Upside for Replimune
ca.finance.yahoo.com - April 24 at 5:23 AM
Genentech oncology exec jumps to Replimune to get cancer-killing meds to marketGenentech oncology exec jumps to Replimune to get cancer-killing meds to market
fiercebiotech.com - April 21 at 6:32 PM
Ex­clu­sive: Genen­techs for­mer Tecen­triq CEO jumps ship to head up com­mer­cial at an on­colyt­ic virus play­erEx­clu­sive: Genen­tech's for­mer Tecen­triq 'CEO' jumps ship to head up com­mer­cial at an on­colyt­ic virus play­er
endpts.com - April 21 at 8:31 AM
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial OfficerReplimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
finance.yahoo.com - April 21 at 8:31 AM
Replimune Group, Inc. (NASDAQ:REPL) COO Sells $918,900.00 in StockReplimune Group, Inc. (NASDAQ:REPL) COO Sells $918,900.00 in Stock
americanbankingnews.com - April 19 at 7:32 PM
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by BrokeragesReplimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 18 at 2:32 AM
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy ...Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy ...
apnews.com - April 12 at 5:44 PM
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual MeetingReplimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 12 at 5:44 PM
What Did We Learn From Replimune Group, Inc. (NASDAQ:REPL) Insider Trading?What Did We Learn From Replimune Group, Inc. (NASDAQ:REPL) Insider Trading?
stocksregister.com - March 27 at 9:01 PM
Replimune Group Inc (REPL) COO Colin Love Sold $1 million of SharesReplimune Group Inc (REPL) COO Colin Love Sold $1 million of Shares
finance.yahoo.com - March 18 at 2:24 AM
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
finance.yahoo.com - March 11 at 5:36 PM
DateCompanyBrokerageAction
4/26/2021AlectorMorgan StanleyBoost Price Target
1/15/2021AlectorBank of AmericaInitiated Coverage
11/11/2020AlectorSmith Barney CitigroupLower Price Target
7/29/2020AlectorBarclaysLower Price Target
6/24/2020AlectorHC WainwrightInitiated Coverage
4/28/2020AlectorThe Goldman Sachs GroupInitiated Coverage
3/5/2020AlectorCitigroupInitiated Coverage
2/18/2020AlectorStifel NicolausInitiated Coverage
12/16/2019AlectorCowenReiterated Rating
11/27/2019AlectorBTIG ResearchInitiated Coverage
3/4/2019AlectorSVB LeerinkInitiated Coverage
2/11/2021AlloVirPiper SandlerBoost Price Target
8/24/2020AlloVirJPMorgan Chase & Co.Initiated Coverage
1/20/2021REGENXBIORoyal Bank of CanadaBoost Price Target
1/6/2021REGENXBIORaymond JamesUpgrade
12/15/2020REGENXBIOUBS GroupInitiated Coverage
8/14/2020REGENXBIOChardan CapitalReiterated Rating
11/11/2019REGENXBIOEvercore ISIReiterated Rating
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
10/12/2020ImmunovantGuggenheimInitiated Coverage
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
11/6/2020Replimune GroupBMO Capital MarketsBoost Price Target
11/2/2020Replimune GroupJefferies Financial GroupInitiated Coverage
10/14/2020Replimune GroupRoth CapitalBoost Price Target
6/3/2020Replimune GroupWedbushReiterated Rating
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.